ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells $432,660.54 in Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Elizabeth H.Z. Thompson sold 16,558 shares of the business’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the transaction, the executive vice president owned 18,994 shares of the company’s stock, valued at $496,313.22. This trade represents a 46.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $25.87 on Monday. The stock has a market cap of $4.43 billion, a price-to-earnings ratio of 11.76, a PEG ratio of 17.94 and a beta of 0.81. ACADIA Pharmaceuticals Inc. has a 1 year low of $19.69 and a 1 year high of $28.35. The business has a fifty day moving average of $23.74 and a 200-day moving average of $23.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $268.10 million for the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. ACADIA Pharmaceuticals’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.11 earnings per share. On average, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.39 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Canaccord Genuity Group boosted their price target on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. BMO Capital Markets increased their price objective on shares of ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, July 21st. Stifel Nicolaus raised their price objective on shares of ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 21st. HC Wainwright cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 30th. Finally, Citigroup upped their target price on ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Thirteen investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.31.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ACAD. Farther Finance Advisors LLC grew its stake in shares of ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 386 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of ACADIA Pharmaceuticals by 15.6% in the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 402 shares in the last quarter. Cetera Investment Advisers lifted its stake in ACADIA Pharmaceuticals by 2.7% during the fourth quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company’s stock valued at $437,000 after purchasing an additional 436 shares during the last quarter. J.W. Cole Advisors Inc. lifted its stake in ACADIA Pharmaceuticals by 2.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company’s stock valued at $551,000 after purchasing an additional 501 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its holdings in ACADIA Pharmaceuticals by 2.0% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,666 shares of the biopharmaceutical company’s stock worth $766,000 after buying an additional 566 shares in the last quarter. 96.71% of the stock is owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.